BROOKS LABORATORIES LIMITED

BSE: BROOKS533543ISIN INE650L01011

Healthcare
Pharmaceuticals

Share price

₹65.91+1.23 (+1.90%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹111.55
52W low: ₹36.90
Off 52W high: -40.91%
1M return: +20.54%
3M return: +8.94%
6M return: +16.90%
1Y return: -40.54%
20D avg volume: 25,103
50 DMA: ₹62.89
200 DMA: ₹63.54

Key ratios Consolidated

Market cap: ₹194.15 Cr
Current price: ₹65.91
52W high / low: ₹111.55 / ₹36.90
Face value: ₹10.00
P/E: 14.70
P/B: 1.58
EPS (TTM): ₹4.49
Book value / share: ₹41.64
ROE: —
ROCE: 5.30%
Operating margin: —
Net margin: —
Debt / equity: 0.06
Net debt: ₹0.69 Cr
Interest cover: 7.90
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 66.8 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	22.96	20.21	16.57	23.45	25.51	23.32	20.52	20.79	17.93	—
	0.18	0.44	0.12	0.39	0.22	0.62	0.03	0.20	0.07	—
	23.14	20.65	16.69	23.84	25.73	23.94	20.54	20.99	18.00	—
	21.72	20.03	16.39	21.60	23.08	22.43	19.61	20.04	18.21	—
	13.68	11.81	9.08	10.42	13.62	13.68	12.17	11.40	9.80	—
	0.14	0.03	1.49	3.00	2.41	1.72	1.19	1.24	3.03	—
	4.21	3.85	3.72	3.93	3.67	3.38	3.29	3.21	3.07	—
	0.21	0.09	0.16	0.28	0.30	0.26	0.28	0.32	0.16	—
	0.42	0.41	0.39	0.39	0.39	0.39	0.38	0.43	0.40	—
	4.20	3.26	3.12	3.29	2.82	2.58	2.88	2.87	2.27	—
	1.42	0.61	0.30	2.24	2.65	1.51	0.94	0.96	-0.21	—
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
	1.42	0.61	0.30	2.24	2.65	1.51	0.94	0.96	-0.21	—
	0.00	0.00	0.00	0.00	0.00	0.18	0.00	0.00	0.00	—
	-1.79	1.52	5.50	7.98	9.59	-1.46	-2.13	-3.96	-2.41	—
	-0.61	0.52	1.87	2.71	3.25	-0.54	-0.82	-1.51	-0.94	—
Key metrics
	2.05	1.11	0.85	2.91	3.34	2.16	1.60	1.71	0.35	—
	8.90%	5.50%	5.10%	12.40%	13.10%	9.30%	7.80%	8.20%	2.00%	—
	-7.80%	7.50%	33.20%	34.00%	37.60%	-6.30%	-10.40%	-19.00%	-13.40%	—
	—	0.60%	—	2.10%	—	1.80%	—	—	—	—
	-10.00%	-13.30%	-19.20%	12.80%	42.30%	—	—	—	—	—
	-118.70%	204.10%	358.20%	301.50%	497.90%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	83.19	85.74	82.56	—
	1.13	1.17	0.88	—
	84.32	86.91	83.44	—
	79.74	81.10	80.25	—
	44.99	49.61	47.04	—
	4.66	2.25	7.18	—
	15.71	15.16	12.96	—
	0.74	0.84	1.03	—
	1.61	1.59	1.60	—
	13.87	12.49	10.59	—
	4.57	5.80	3.19	—
	0.00	0.00	0.00	—
	4.57	5.80	3.19	—
	0.00	0.00	0.18	—
	13.21	24.58	-9.97	—
	4.49	8.35	-3.72	—
Key metrics
	6.92	8.23	5.82	—
	8.32%	9.60%	7.00%	—
	15.88%	28.70%	-12.10%	—
	—	5.30%	4.20%	—
	-7.71%	3.90%	—	—
	547.55%	346.50%	—	—
	—	5.78	1.60	—
	—	0.38	-0.25	—
	—	0.06	0.06	—
	—	0.69	6.02	—
	—	66.8	68.9	—
Balance sheet
	—	148.17	123.69	—
	—	37.42	33.88	—
	—	6.59	0.04	—
	—	16.11	19.99	—
	—	11.02	9.20	—
	—	2.43	2.29	—
	—	13.41	12.51	—
	—	11.44	13.62	—
	—	21.81	22.84	—
	—	7.28	6.06	—
	—	6.09	5.93	—
	—	1.19	0.13	—
	—	122.66	98.10	—
Cash flow
	—	9.29	2.52	—
	—	-2.92	-45.97	—
	—	0.17	43.36	—
	—	3.51	0.92	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24
Income statement
	22.96	20.21	16.57	23.45	25.51	23.32	20.52	20.79	17.93	—
	0.18	0.44	0.12	0.39	0.22	0.62	0.03	0.20	0.07	—
	23.14	20.65	16.69	23.84	25.73	23.94	20.54	20.99	18.00	—
	21.72	20.03	16.39	21.60	23.08	22.39	19.61	20.04	18.21	—
	13.68	11.81	9.08	10.42	13.62	13.68	12.17	11.40	9.80	—
	0.14	0.03	1.49	3.00	2.41	1.72	1.19	1.24	3.03	—
	4.21	3.85	3.72	3.93	3.67	3.38	3.29	3.21	3.07	—
	0.21	0.09	0.16	0.28	0.30	0.26	0.28	0.32	0.16	—
	0.42	0.41	0.39	0.39	0.39	0.39	0.38	0.43	0.40	—
	4.20	3.26	3.12	3.29	2.82	2.55	2.89	2.87	2.27	—
	1.42	0.61	0.30	2.24	2.65	1.55	0.94	0.96	-0.21	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—
	1.42	0.61	0.30	2.24	2.65	1.55	0.94	0.96	-0.21	—
	0.00	0.00	0.00	0.00	0.00	0.18	—	—	—	—
	1.42	0.61	0.30	2.24	2.65	1.37	0.94	0.96	-0.21	—
	0.48	0.21	0.10	0.76	0.90	0.51	0.36	0.36	-0.08	—
Key metrics
	2.05	1.11	0.85	2.91	3.34	2.20	1.60	1.71	0.35	—
	8.90%	5.50%	5.10%	12.40%	13.10%	9.40%	7.80%	8.20%	2.00%	—
	6.20%	3.00%	1.80%	9.60%	10.40%	5.90%	4.60%	4.60%	-1.20%	—
	—	0.60%	—	2.10%	—	1.50%	—	—	—	—
	-10.00%	-13.30%	-19.20%	12.80%	42.30%	—	—	—	—	—
	-46.40%	-55.50%	-68.10%	133.30%	1,361.90%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	83.19	85.74	82.56	—
	1.13	1.17	0.88	—
	84.32	86.91	83.44	—
	79.74	81.10	80.21	—
	44.99	49.61	47.04	—
	4.66	2.25	7.18	—
	15.71	15.16	12.96	—
	0.74	0.84	1.03	—
	1.61	1.59	1.60	—
	13.87	12.49	10.55	—
	4.57	5.80	3.23	—
	0.00	0.00	0.00	—
	4.57	5.80	3.23	—
	0.00	0.00	0.18	—
	4.57	5.80	3.05	—
	1.55	1.97	1.14	—
Key metrics
	6.92	8.23	5.86	—
	8.32%	9.60%	7.10%	—
	5.49%	6.80%	3.70%	—
	—	5.30%	3.60%	—
	-7.71%	3.90%	—	—
	-22.80%	90.20%	—	—
	—	5.78	1.60	—
	—	1.60	0.83	—
	—	0.06	0.05	—
	—	0.69	6.02	—
	—	66.8	68.9	—
Balance sheet
	—	146.36	140.66	—
	—	37.42	33.88	—
	—	6.59	0.04	—
	—	16.11	19.99	—
	—	11.02	9.20	—
	—	2.43	2.29	—
	—	13.41	12.51	—
	—	11.44	13.62	—
	—	21.81	22.84	—
	—	7.28	6.06	—
	—	6.09	5.93	—
	—	1.19	0.13	—
	—	120.84	115.07	—
Cash flow
	—	9.29	2.52	—
	—	-2.92	-45.97	—
	—	0.17	43.36	—
	—	3.51	0.92	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -7.71%
Profit YoY (TTM): -22.80%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): -7.71%
Profit YoY (TTM): +547.55%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 52.62%

Holder	Type	Holding	Previous	Change
Atul Ranchal	Promoter	19.24%	—	—
Rajesh Mahajan	Promoter	17.36%	—	—
Quant Mutual Fund - Quant Business Cycle Fund	Public	9.90%	—	—
Erwin Mahajan	Promoter Group	4.10%	—	—
Rajni Ranchal	Promoter Group	2.92%	—	—
Savvy Ranchal	Promoter Group	2.67%	—	—
Aryan Mahajan	Promoter Group	2.47%	—	—
Saras Gupta	Promoter Group	2.34%	—	—
Selina Ranchal	Promoter Group	1.52%	—	—
Saumik Ketankumar Doshi	Public	1.20%	—	—
One Up Financial Consultants Pvt Ltd	Public	1.02%	—	—
Davinder Kumari	Promoter Group	0.00%	—	—
Manmohan Lal Mahajan	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
BROOKS LABORATORIES LIMITED	194	65.91	14.70	5.30%	-7.71% TTM	+547.55% TTM	-40.54%

Filings & corporate actions

Recent announcements

Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2026 ,inter alia, to consider and approve the Unaudited Standalone ....3 Nov 2026 · Board Meeting / Board Meeting
Brooks Laboratories Limited has informed the BSE that the meeting of Board of Directors of the Company is scheduled on 07/11/2026, inter alia, to consider and approve take on records the ....3 Nov 2026 · Others / Reg. 50 (1) - Prior intimation about Board meeting under Regulation 50(1))
Outcome of Board Meeting under Regulation 30 of LODR for the Scheme of Arrangement14 Oct 2026 · Company Update / Scheme of Arrangement
Outcome of Board Meeting held on Wednesday, October 14, 202614 Oct 2026 · Others / Outcome without intimation
please find attached for clarification for movement in price13 Oct 2026 · Company Update / General
The Exchange has sought clarification from Brooks Laboratories Ltd on October 12, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant ....12 Oct 2026 · Company Update / Clarification
Please find attached coverletter alongwith certificate under regulation 74(5).9 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window.22 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Resignation of Ms. Krutika Rane as Company Secretary and Compliance Officer of the Company with effect from 9th October 2026.16 Sep 2026 · Company Update / Resignation of Company Secretary / Compliance Officer
Newspaper Publication regarding re-lodgement of transfer deed.16 Sep 2026 · Company Update / Newspaper Publication
Scrutinizer Report alongwith voting results for the AGM held on September 3, 2026.4 Sep 2026 · AGM/EGM / AGM
Proceedings of the 24th AGM held on Thursday, September 3, 2026.3 Sep 2026 · AGM/EGM / AGM
Please find enclosed herewith Addendum to the Notice of 24th Annual General Meeting.22 Aug 2026 · Company Update / Newspaper Publication
Please find attached addendum to the notice of 24th Annual General Meeting.21 Aug 2026 · AGM/EGM / AGM
Addendum to the Notice of 24th Annual General Meeting of the Company.21 Aug 2026 · Others / Reg. 34 (1) Annual Report
Intimation of Record date, E-Voting dates and Book Closure date.17 Aug 2026 · Corp. Action / Book Closure
Newspaper publication dated 14th August 2026 of Unaudited Financial Results for the quarter ended 30th June 2026.14 Aug 2026 · Company Update / Newspaper Publication
Financial Results for quarter ended June 30,2026.13 Aug 2026 · Result / Financial Results
Outcome of Board Meeting held on Thursday, 13th August, 202613 Aug 2026 · Board Meeting / Outcome of Board Meeting
Newspaper publication regarding 24th AGM of the Company to be held on 3rd September 2026.13 Aug 2026 · Company Update / Newspaper Publication
Letter to the Shareholders-Annual Report for the FY 2025-2612 Aug 2026 · Company Update / General
Notice of 24th Annual General Meeting of the Company to be held on 3rd September 2026 through VC/OAVM.12 Aug 2026 · AGM/EGM / AGM
Pursuant to Regulation 34 read with Regulation 30 of SEBI Listing Regulations, we are enclosing herewith the following: 1. Notice of the AGM.2. Annual Report for the Financial Year 2025-26.12 Aug 2026 · Others / Reg. 34 (1) Annual Report
Newspaper Advertisement - Intimation of 24th Annual General Meeting of the Company through VC/OAVM.7 Aug 2026 · Company Update / Newspaper Publication
Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve and take on record the ....6 Aug 2026 · Board Meeting / Board Meeting
Appointment of Mr. Rajesh Mahajan as President - Trading.17 Jul 2026 · Company Update / Change in Management
We hereby inform that, further to the disclosure made by the Company on 19th June 2026 regarding proposed sale of a portion of its shareholding in Brooks Steriscience Limited.16 Jul 2026 · Company Update / Memorandum of Understanding /Agreements
Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018 for quarter ended 30th June 2026.9 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Incorporation of Wholly Owned Subsidiary.2 Jul 2026 · Company Update / General
Intimation of Closure of Trading Window.23 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
With reference to corporate announcement titled "Partial Sale of Equity Shares held in Brooks Steriscience Limited" submitted by the Company on 19th June 2026, we wish to inform you that ....20 Jun 2026 · Company Update / General
We hereby inform that the Company at its board meeting held today i.e 19th June 2026 has approved sale of 51,220 equity shares held by the Company in Brooks Steriscience Limited to Steriscience ....19 Jun 2026 · Company Update / General
Newspaper Publication dated 30th May 2026 of Audited Financial Results for the quarter and year ended 31st March 2026.30 May 2026 · Company Update / Newspaper Publication
Annual Secretarial Compliance Report of the financial year ended 31st March 202629 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Appointment of Chief Executive Officer.29 May 2026 · Company Update / Change in Management
Outcome of Board Meeting held on Held On Friday, 29th May 2026.29 May 2026 · Board Meeting / Outcome of Board Meeting
Outcome of the Board Meeting held on Friday, 29th May 202629 May 2026 · Result / Financial Results
Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve and take on record the ....22 May 2026 · Board Meeting / Board Meeting
Update on Scheme of Arrangement involving Brooks Steriscience Limited ("BSL"), a Joint Venture / Associate of the Company.14 May 2026 · Company Update / General
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....29 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Board meetings

7 Nov 2026 Board Meeting - Financial Results
13 Aug 2026 Board Meeting - Financial Results